SCHEMBL17468147

SCHEMBL17468147

O=c1cc(Cl)n(CCO)c(=O)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UNG P13051 3/20 0.41
ALDH1A1 P00352 6/20 0.40
HPGD P15428 3/20 0.40
CYP3A4 P08684 3/20 0.40
KMT2A Q03164 5/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 4/20 0.38
MAPT P10636 3/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
PKM P14618 1/20 0.37
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.35
MPO P05164 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
BLM P54132 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742355 0.81 MAPT (0.41) ALDH1A1HPGDCYP3A4KMT2AL3MBTL1
SCHEMBL3985429 0.79 MAPT (0.44) UNGALDH1A1HPGDKMT2AMEN1
SCHEMBL31135156 0.79 ALDH1A1 (0.38) UNGALDH1A1HPGDCYP3A4KMT2A
SCHEMBL18072360 0.78 HSD17B10 (0.53) UNGALDH1A1KMT2AL3MBTL1MEN1
SCHEMBL3193701 0.78 KMT2A (0.61) UNGALDH1A1HPGDCYP3A4KMT2A
SCHEMBL9257137 0.77 KMT2A (0.51) ALDH1A1HPGDCYP3A4KMT2AL3MBTL1
SCHEMBL2678032 0.76 KMT2A (0.46) ALDH1A1HPGDCYP3A4KMT2AL3MBTL1
SCHEMBL17467913 0.74 ALDH1A1 (0.40) ALDH1A1HPGDCYP3A4KMT2AL3MBTL1
SCHEMBL8195993 0.73 ALDH1A1 (0.43) UNGALDH1A1HPGDCYP3A4KMT2A
SCHEMBL9289331 0.73 CYP3A4 (0.44) ALDH1A1HPGDCYP3A4KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300965-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-12 US disclosed
US-11999746-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-06-04 US disclosed
US-20200055863-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-20 US disclosed
US-20200055863-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-20 US disclosed
US-10428078-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-01 US disclosed
US-10428078-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-01 US disclosed
EP-3172211-B1 TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 GLAXOSMITHKLINE IP DEV LTD (GB) 2019-07-03 EP disclosed
EP-3172211-B1 TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 GLAXOSMITHKLINE IP DEV LTD (GB) 2019-07-03 EP disclosed
US-20190023715-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-24 US disclosed
US-20190023715-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-24 US disclosed
US-10125141-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-11-13 US disclosed
US-20170204109-A1 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-07-20 US disclosed
US-20170204109-A1 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-07-20 US disclosed
US-20170204109-A1 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-07-20 US disclosed
WO-2016011930-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055863-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885
US-20190023715-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885
US-10125141-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885
US-10428078-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885
US-20240300965-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885
US-11999746-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885
US-20170204109-A1 Compounds PLAAT2, PLA2G12A, PLA2G1B UNG 4080/4885ALDH1A1 2222/4885HPGD 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.